ABSTRACT
ABSTRACT Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practices. Recently, their use has expanded to other cultures. Hallucinogens are natural or synthetic substances that alter the perception of reality at nontoxic doses, producing intense psychological and physiological effects. The initial research on hallucinogens began in the 1950s. However, their non-medical use, studies without proper controls, and negative social opinion resulted in legal restrictions that limited their use for clinical and preclinical research for more than two decades. A renewed interest in studying hallucinogens as potential therapeutic agents for treating different psychiatric conditions has recently re-emerged. This review summarizes the effects of main hallucinogen drugs and their therapeutic potential. Classic hallucinogens such as LSD, dimethyltryptamine, psilocin, and mescaline have chemical structures similar to serotonin and directly activate 5-hydroxy-tryptamine (5-HT2A) receptors. Ketamine is a dissociative anesthetic with antagonist effects at the glutamatergic N-methyl-D-aspartate receptor, indirectly activating 5-HT2A receptors. Ketamine has rapid antidepressant effects and reduces suicidal ideation, but its effects are short-lasting. Other hallucinogens are under study. It is necessary to continue this research with a more rigorous methodology and include studying the long-term effects of psychedelics use.
ABSTRACT
Depression is a common psychiatric disease that seriously affects the physical and mental health and quality of life of patients， and has become one of the major global disease burdens. The etiology of depression is intricate， and despite extensive research， its pathogenesis remains inconclusive， resulting in various hypotheses of its onset mechanisms. Presently， the primary approach for clinically treating depression involves the utilization of selective inhibitors targeting the reuptake of monoamine neurotransmitters within the central nervous system. However， these drugs are generally characterized by delayed onset of action， limited efficacy and obvious resistance. Recently， researchers have gradually turned their attention to the development of antidepressant drugs with novel mechanisms. Notably， as a category of abundantly available active ingredients in Chinese medicine， numerous pharmacological studies have demonstrated that oligosaccharides and polysaccharides possess promising antidepressant properties， such as Morindae Officinalis Radix oligosaccharides， Polygalae Radix oligosaccharide esters， Poria polysaccharides and Astragali Radix polysaccharides. Their pharmacological mechanisms are various， including enhancing the levels of monoamine neurotransmitters in the brain， inhibiting the hyperactivation of the hypothalamic-pituitary-adrenal axis（HPA axis）， increasing the expression of neurotrophic factors（NTF）， regulating immune-inflammatory responses and modulating the microbiota-gut-brain axis. Therefore， oligosaccharides and polysaccharides from Chinese medicine have become a vital source of safe and effective novel antidepressant candidates due to the potential to improve depression through integrated regulatory effects. This article aims to provide a comprehensive and systematic review of recent progress to contribute to the elucidation of the mechanisms underlying the antidepressant effects of oligosaccharides and polysaccharides derived from Chinese medicine.
ABSTRACT
Depression, a chronic syndrome with significant and lasting depression and sleep disturbance, is the most common mental disorder.Recent studies have shown that melatonin plays an important role in the occurrence and development of depression.rI1iis review describes the antidepressant effects of melatonin from HPA axis, cytokines, neurosynaptic plasticity and monoamine neurotransmitters, and summarizes the melatonin receptor agonists agomelatine, ramelteon and piromelatine antidepressant effects.A theoretical basis is expected to provide a reference for the study of melatonin's antidepressant mechanism.
ABSTRACT
The dried roots of Berberis heteropoda Schrenk have traditionally been used to treat acute gastroenteritis and dysentery. The aim of this study was to confirm the antibacterial activity of an extract of Berberis heteropoda Schrenk rootin vitro and its therapeutic effects on rats with diarrhea-predominant irritable bowel syndrome (D-IBS) in vivo, as well as to identify the related signaling pathways. A water extract of Berberis heteropoda Schrenk root (BHS) inhibited the growth of S. aureus, E. coli, P. aeruginosa and S. faecalis. BHS potentially damaged the structure of the bacterial cell membrane and decreased the activity of some membranous enzymes, eventually killing the S. aureus, E. coli, P. aeruginosa and S. faecalis bacteria. Oral administration of BHS (low, middle and high dose group, L, M and H) significantly alleviated the abdominal pain, diarrhea, and depression-like symptoms of D-IBS rats, and the efficacy index ranged from 30% to 60%, indicating that the BHS treatment was effective. BHS (L, M and H) alleviated the abnormal pathological changes in the brain, as evidenced by HE staining. The expression of CHAT, 5-HT, C-FOS and CGRP was reduced by the BHS treatment (L, M and H). Our findings provide novel insights into the use of the natural product BHS to inhibit pathogenic bacteria by destroying the bacterial structure, indicating that BHS possesses certain biological activities. Furthermore, BHS has the potential to alleviate diarrhea, abdominal pain and depression-like behaviors in D-IBS rats by regulating the brain-gut peptide levels.
ABSTRACT
p11 protein (S100A10) is downregulated in depressive-like states of human and rodent. Antidepressant drug treatment increases p11 levels in rodent models. We reviewed studies demonstrating that p11 levels are regulated in depression and by antidepressant treatment and that p11 upregulation exerts antidepressant effects. Current studies on p11 underscore the importance of p11 as a potential antidepressant target.
Subject(s)
Humans , Depression , Rodentia , Up-RegulationABSTRACT
Acantholippia deserticola (Phil.ex F. Phil.) Moldenke is a Verbenaceae that has long been used in traditional medicine in Tarapacá (Chile) as an analgesic, anti-inflammatory and aphrodisiac agent. Sincé alpha - and beta -thujone were identified as the main constituents (88.4 percent) of the essential oil from this plant, we investigated its biological properties. The results show that the essential oil from Acantholippia deserticola decreased locomotive and rearing activity compared to control group rats, including those treated with diazepam, but the essential oil had no effects on head movements or grooming. The essential oil also had significant anxiolytic and antidepressant effects. This essential oil, therefore, has sedative, anxiolytic and antidepressant actions on the rat central nervous system.
Acantholippia deserticola es una Verbenaceae de uso en la medicina tradicional como analgésico, antiinflamatorio y afrodisíaco en la región de Tarapacá, Chile. En el aceite esencial se ha identificado alfa - and beta -tuyonas como principales constituyentes (88.4 por ciento) de esta planta, que ha llevado a investigar sus propiedades biológicas. Los resultados muestran que el aceite esencial de Acantholippia deserticola disminuye la locomoción y el levantamiento en dos patas, en comparación con el grupo control, incluido el tratado por el diazepam, pero el aceite esencial no tuvo efecto sobre la sacudida de cabeza y el acicalamiento. En ambas pruebas, se observa un efecto significativo del aceite esencial en los efectos ansiolíticos y antidepresivos, lo que indica que el aceite esencial tiene actividad sedante, ansiolítica y antidepresiva en el sistema nervioso central.